Metyrosine in psychosis associated with 22q11.2 deletion syndrome: Case report

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 1, 2007, Pages 115-120

  Carandang, Carlo G ^a,b   Scholten, Monique C ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b IWK HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CATECHOL METHYLTRANSFERASE; METHYLPHENIDATE; METIROSINE;

ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE TITRATION; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; HEART VENTRICLE SEPTUM DEFECT; HUMAN; MALE; MENTAL INSTABILITY; PSYCHOSIS; SCHOOL; STRUCTURED INTERVIEW; SUICIDE ATTEMPT; VELOCARDIOFACIAL SYNDROME;

ADOLESCENT; ALPHA-METHYLTYROSINE; AMBULATORY CARE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; DIGEORGE SYNDROME; ENZYME INHIBITORS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PATIENT READMISSION; PSYCHOTIC DISORDERS; SOCIAL BEHAVIOR; TYROSINE 3-MONOOXYGENASE;

EID: 33947365208     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0013     Document Type: Article

References (30)

1. Addington D, Bouchard RH, Goldberg J, Honer B, Malla A, Norman R, Tempier R, Berzins S: Clinical practice guidelines treatment of schizophrenia. Can J Psychiatry 50(Supp 1):1s-56s, 2005.
2. Anden NE: Effects of Reserpine and a tyrosine hydroxylase inhibitor on the monoamine levels in different regions of the rat central nervous system. Eur J Pharmacol. 1:1-5, 1967.
3. Bassett AS, Chow EWC, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R: The schizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatry 160:1580-1586, 2003.
4. Bassett AS, Chow EWC, Husted J, Weksberg R, Caluseriu O, Webb GD, Gatzoulis MA: Clinical features of 78 adults with 22q11 deletion syndrome. Am J Med Gen A 138:307-313, 2005.
5. Beauchesne LM, Warnes CA, Connolly HM, Ammash NM, Grogan M, Jalal SM, Michels W: Prevalence and clinical manifestations of 22q11.2 microdeletion in adults with selected conotruncal anomalies. J Am Coll Cardiol 45:595-598, 2005.
6. Berman RM, Narasimhan M, Miller HL, Anand A, Cappiello A, Oren DA, Heninger GR, Charney DS: Transient depressive relapse induced by catecholamine depletion: Potential phenotypic vulnerability marker? Arch Gen Psychiatry 56: 395-403, 1999.
7. Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA, Merritt RK, O'Leary LA, Wong, L-Y, Elixson EM, Mahle WT, Campbell RM: A population-based study of the 22q11.2 deletion: Phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112:101-107, 2003.
8. Gothelf D, Frisch A, Munitz H, Rockah R, Laufer N, Mozes T, Hermesh H, Weizman A, Frydman M: Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome. Schizophrenia Res 35:105-112, 1999.
9. Gothelf D, Presburger G, Zohar AH, Burg M, Nahmani A, Frydman M, Shohat M, Inbar D, Aviram-Goldring A, Yeshaya J, Steinberg T, Finkelstein Y, Frisch A, Weizman A, Apter A: Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. Am J Med Genet B Neuropsychiatr Genet 126:99-105, 2004.
10. Graf WD, Unis AS, Yates CM, Sulzbacher S, Dinulos MB, Jack RM, Dugaw KA, Paddock MN, Parson WW: Catecholamines in patients with 22q11.2 deletion syndrome and the low activity COMT polymorphism. Neurology 57:410-416, 2001.
11. Grossman MH, Emanuel BS, Budarf ML: Chromosomal mapping of the human catechol-O-methyltranferase gene to 22q11.1 q11.2. Genomics 12:822-825, 1992.
12. Herken H, Erdal ME: Catechol-O-methyltransferase gene polymorphism in schizophrenia: Evidence for association between symptomology and prognosis. Psychiatr Genet 11:105-109, 2001.
13. Horowitz A, Shifman S, Rivlin N, Pisante A, Darvasi A: A survey of the 22q11 microdeletion in a large cohort of schizophrenia patients. Schizophr Res 73:263-267, 2005.
14. Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J, Gos A, Nestadt G, Wolyniec PS, Lasseter VK, Eisen H, Childs B, Kazazian HH, Kucherlapatis R, Antonarakis SE, Pulver AE, Housman DE: Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Genetics 92:7612-7616, 1995.
15. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, Goldberg R, Kucherlapati R, Papolos DF: Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velocardio-facial syndrome. Am J Med Gen (Neuropsychiatric Genetics) 67:468-472, 1996.
16. Lam RW, Tam EM, Grewal A, Yatham LN: Effects of alpha-methyl-para- tyrosine-induced catecholamine depletion in patients with seasonal affective disorder in summer remission Neuropsychopharmacology 25(5 Suppl):S97-S101, 2001.
17. Longhurst JG, Carpenter LL, Epperson CN, Price LH, McDougle CJ: Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder. Biol Psychiatry 46:573-576, 1999.
18. Malmfors T: Fluorescent histochemical studies on the uptake, storage and release of catecholamines. Circ Res Supp 3, 20-21:25-42, 1967.
19. Murphy KC, Jones LA, Owen MJ: High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56:940-945, 1999.
20. Murphy K: Schizophrenia and velo-cardio-facial syndrome. Lancet 359:426-430, 2002.
21. Oskarsdottir S, Persson C, Eriksson BO, Fasth A: Presenting phenotype in 100 children with the 22q11 deletion syndrome. Eur J Pediatr 164: 146-153, 2005.
22. Papolos DF, Faedda GL, Veit S, Goldberg R, Morrow B, Kucherlapati R, Shprintzen RJ: Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: Does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder? Am J Psychiatry 153: 1541-1547, 1996.
23. Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, Wolyniec PS, Morrow B, Karayiorgou M, Antonarakis SE, Housman D, Kucherlapati R: Psychotic illness in patients diagnosed with velocardio-facial syndrome and their relatives. J Nerv Ment Dis 182:476-478, 1994.
24. Ryan AK, Goodship JA, Wilson DI, Philip N, Levy A, Seidel H, Schuffenhauer S, Oechsler H, Belohradsky B, Prieur M, Aurias A, Raymond FL, Clayton-Smith J, Hatchwell E, McKeown C, Beemer FA, Dallapiccola B, Novelli G, Hurst JA, Ignatius J, Green AJ, Winter RM, Brueton L, Brondum-Nielsen K, Scambler PJ, Stewart F, Van Essen T, Patton M, Paterson J: Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: A European collaborative study. J Med Gen 34:798-804, 1997.
25. Scambler PJ, Kelly D, Lindsay E, Williamson R, Goldberg R, Shprintzen R, Wilson DI, Goodship JA, Cross IE, Burn J: Velo-cardio-facial syndrome associated with chromosome 22 deletions encompassing the DiGeorge locus. Lancet 339: 1138-1139, 1992.
26. Shprintzen RJ, Goldberg R, Golding-Kushner KJ, Marion RW: Late onset psychosis in the velocardio-facial syndrome. Am J Med Gen. 42: 141-142, 1992.
27. Sjostrom R: Effects of α-methyltyrosine on the cerebrospinal fluid content of HVA and 5-HIAA in man. Psychopharmacologia 22:214-216, 1971.
28. Weinshilboum RM, Raymond FA: Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am J Med Genet 29:125-135, 1977.
29. Winqvist R, Lundstrom K, Salminen M, Laatikainen M, Ulmanen I: The human catechol-O-methytransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BglI. Cytogenet Cell Genet 59:253-257, 1992.
30. Yagi H, Furutani Y, Hamada H, Sasaki T, Asakawa S, Minoshima S, Ichida F, Joo K, Kimura M, Imamura S, Kamatani N, Momma K, Takao A, Nakazawa M, Shimizu N, Matsuoka R: Role of TBX1 in human del22q11.2 syndrome. Lancet 362:1366-1373, 2003.